Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine premedication for anxiety during electroconvulsive therapy
IRCT20211011052726N7Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine in anxiety disorder (4 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Anxiety level, Seizure duration and 3 more. Started May 2026; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on IRCT20211011052726N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211011052726N7.